RCS - Ondine Biomedical - Ondine unveils new research at SPIE Photonics West

Ondine BiomedicalAnnouncement

26/01/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240126:nRSZ0417Ba&default-theme=true

RNS Number : 0417B  Ondine Biomedical Inc.  26 January 2024

Non-regulatory announcement

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Ondine unveils new research at SPIE Photonics West

Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) will present
new research at the SPIE Photonics West
(https://spie.org/conferences-and-exhibitions/photonics-west#_=_) conference
in San Francisco, California. The presentation will provide details of an
exploratory study showing that photodisinfection significantly reduces
pathogens in the nose - a reservoir for bacteria - yet does not produce
long-term adverse effects on the nasal microbiome.(1) Organised by SPIE, the
international society for optics and photonics, SPIE Photonics West is the
largest annual event for optic and photonic technologies and one of the
largest scientific conferences in the world.

These results demonstrate that Steriwave is an effective, potent,
short-acting, and non-selective method of nasal decolonization, while
permitting rapid recovery of the native microbiome at one week after
treatment. The study involved analyzing nasal swabs from 35 healthy volunteers
after being treated with Ondine's Steriwave® Nasal Photodisinfection System.

The oral presentation will be delivered by Ondine's Director of Research and
Development, Dr Caetano Sabino, at 9am on Tuesday, 30 January 2024, as part of
the "Photonic Diagnosis, Monitoring, Prevention, and Treatment of Infections
and Inflammatory Diseases" session.

The "Microbiome Analysis of Photodynamic Nasal Decolonization" abstract can be
accessed here
(https://spie.org/photonics-west/presentation/Microbiome-Analysis-of-Photodynamic-Nasal-Decolonization/12822-55?enableBackToBrowse=true#_=_)
.

_________

(1) The nasal microbiome consists of a complex community of microorganisms -
fungi, parasites, viruses, and bacteria - that can act in a symbiotic
relationship in the nasal cavity.

 

**ENDS**

 

 Ondine Biomedical Inc.
 Carolyn Cross, CEO                                           +001 (604) 665 0555

 Singer Capital Markets (Nominated Adviser and Joint Broker)
 Aubrey Powell, Asha Chotai, Sam Butcher                      +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan                               +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                             +44 (0)77 1000 5910

 

About SPIE Photonics West

SPIE Photonics West is the optics and photonics industry's preeminent annual
conference and exhibition and is one of the largest scientific conferences in
the world. Its scope covers all areas regarding the use of light for
scientific and technological applications. The conference brings together tens
of thousands of researchers, innovators, engineers, and business leaders from
across the globe for an engaging week of research sharing, collaboration
forming, and innovation-inspiring exchanges. The week will include more than
4,500 technical presentations as well as showcasing over 1,200 companies in
three focused exhibitions.

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life science company innovating in the
field of photodisinfection therapies. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection platform, in various
stages of development. Ondine's nasal photodisinfection system has a CE mark
in Europe and the UK and is approved in Canada and several other countries
under the name Steriwave®. In the US, it has been granted Qualified
Infectious Disease Product designation and Fast Track status by the FDA and is
currently undergoing clinical trials for regulatory approval. Products beyond
nasal photodisinfection include therapies for a variety of medical indications
such as chronic sinusitis, ventilator-associated pneumonia, burns, and other
indications.

 

About Nasal Photodisinfection

Ondine's Steriwave® Nasal Photodisinfection System is a patented technology
using a proprietary light-activated antimicrobial (photosensitizer) to destroy
pathogens. The photodisinfection treatment is carried out by a trained
healthcare professional and is an easy to use, painless, two-step
process. The photosensitizer is applied to each nostril using a nasal swab,
followed by illumination of the area with a specific wavelength of red laser
light for less than five minutes. The light activates the photosensitizer,
causing an oxidative burst that is lethal to all types of pathogens. A key
benefit of this approach, unlike with antibiotics, is that pathogens do not
develop resistance to the therapy.

Nasal decolonization with antibiotics is already standard practice in many
hospitals prior to surgery, as pathogens in a patient's nasal cavities are a
major cause of surgical site infections (SSIs). Nasal decolonization is
recommended in the 2016 WHO Global guidelines for the prevention of surgical
site infections, 1  and the Society for Healthcare Epidemiology of America
(SHEA) guidelines, published in May 2023, recommend nasal decolonization for
major surgical procedures. 2  However, there is a growing need to reduce
antibiotic use and find non-antibiotic methods of nasal decolonization as
resistance rates have been reported as high as 81%. 3 

 

 1 
https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/ssi/fact-sheet-staphylococcus-web.pdf?sfvrsn=7e7266ed_2

 2  Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent
surgical site infections in acute-care hospitals: 2022 Update. Infect Control
Hosp Epidemiol. 2023;44(5):695-720. doi:10.1017/ice.2023.67

 3  Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical
implications and potential alternatives for the eradication of MRSA. J
Antimicrob Chemother. 2015;70(10):2681-2692. doi:10.1093/jac/dkv169

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRADZGZMVVLGDZG